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Abstract
 Very little is known about the level of infant exposure to manyBackground:
drugs commonly used during breastfeeding. The aim of this study was to
develop a physiologically-based pharmacokinetic (PBPK) model for predicting
infant exposure to maternal efavirenz through breastmilk.
A breastfeeding PBPK model combining whole-body maternal andMethods: 
infant sub-models was constructed from drug-specific and system parameters
affecting drug disposition using mathematical descriptions. The model was
validated against published data on the pharmacokinetics of efavirenz in
nursing mother-infant pairs. Further simulations were conducted to assess
exposure in the context of the 400 mg reduced dose of efavirenz as well as
best- and worse-case scenarios.
 The model adequately described efavirenz pharmacokinetics, withResults:
over 80% of observed data points (203 matched breast milk and plasma pairs)
within the predictive interval. All parameters were within 2-fold difference of
clinical data. Median (range) predicted versus observed breast milk AUC , C
 and C  at the standard 600 mg dose were 75.0 (18.5-324) versus 68.5
(26.3-257) µg.hr/mL, 4.56 (1.17-16.0) versus 5.39 (1.43-18.4) µg/mL, and 2.11
(0.38-12.3) versus 1.68 (0.316-9.57) µg/mL, respectively. Predicted plasma
AUC , C  and C  at 400 mg reduced dose were similar to clinical data
from non-breastfeeding adults. Model-predicted infant plasma concentrations
were similar to clinical data, 0.15 (0.026–0.78) μg/mL at the 400 mg maternal
dose in pooled analysis, approximately 25% lower than simulated exposure at
600 mg. The maximum exposure index was observed in the youngest infants,
5.9% (2.2-20) at 400 mg and 8.7% (3.2-29) at 600 mg. Thirteen and 36% of 10
days-1 month old infants were predicted to have exposure index above the
10% recommended threshold at 400 mg and 600 mg maternal dose,
respectively.
 This application of PBPK modelling opens up opportunities forConclusions:
expanding our understanding of infant exposure to maternal drugs through
breastfeeding.
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Introduction
The re-enactment of The Best Pharmaceuticals for Children 
Act (BPCA), The Pediatric Research Equity Act (PREA) in the 
United States, and The Paediatric Regulation in the European 
Union in 2007 were significant steps in paediatric health promo-
tion. The BPCA and PREA were subsequently made permanent 
by the FDA Safety and Innovation Act in 2012, mandating 
necessary paediatric studies. Although these legal frameworks do 
not remove the ethical and logistical challenges of conduct-
ing research in paediatric patients, they reinforced that children 
should be protected through research, not from it, giving 
impetus to clinical studies in this population. For instance, a 
review of studies conducted under these changes and a break-
down of paediatric studies between September 27, 2007 and 
November 18, 2013 indicated that about 470 paediatric stud-
ies (involving more than 178,000 patients and 160 drugs) 
were completed under BPCA and PREA in the United 
States, reducing off-label paediatric drug use from over 80% 
to about 50%.
However, paediatric drug exposure is not limited to those admin-
istered for specific paediatric indications. More than 90% of 
nursing mothers take at least one drug in the early postna-
tal period, 17% up to 4 months after delivery, and 5% receive 
drugs for chronic conditions1. For most drugs, the level of 
exposure of breastfed infants to maternal drugs through breast 
milk and the potential effects are unknown. At present, there is no 
legislation requiring drug companies to conduct clinical research 
in nursing mother-infant pairs to evaluate infant exposure 
through breast milk. Apparently to avoid legal liability, most 
drugs are labelled not to be used during lactation. However, 
this is not practical in many cases, especially for nursing 
mothers being treated for chronic conditions. For instance, 
under the current WHO guidelines HIV positive nursing moth-
ers take antiretroviral drugs during breastfeeding for their own 
health and/or for prevention of mother-to-child transmission 
of HIV. Understandably, conducting clinical pharmacokinetics 
studies in nursing mother-infant pairs is fraught with ethical and 
logistical challenges.
Physiologically based pharmacokinetic (PBPK) models are 
increasingly being used in paediatric studies, with significant 
regulatory support2,3. In fact, the US FDA Advisory Commit-
tee for Pharmaceutical Science and Clinical Pharmacology 
unanimously voted in support of modelling and simulation for 
paediatric drug development4. Interestingly, the advances in 
PBPK modelling now allow for integration of compartments and 
parameters representing the anatomical and physiological features 
of a nursing woman (system parameters) with physicochemical, 
in vitro, preclinical, and clinical data (drug parameters) to gener-
ate predictions of drug-specific pharmacokinetics. In addition, 
system-specific parameters can be modified for extrapolations 
across different age groups. They also allow for integration 
of maternal and infant anatomy and physiology to simulate 
complex scenarios of infant exposure to substances through 
lactation. However, a cursory literature search indicates that 
the application of PBPK modelling in the study of infant 
exposure to xenobiotics through breast milk has largely been 
limited to environmental risk assessments5–9. Only a single full 
article could be found on use of this approach to describe infant 
exposure to maternal therapeutic drugs through breast milk. 
The model was used to simulate morphine plasma concentra-
tions in infants resulting from codeine use by mothers with fast, 
intermediate, or poor CYP2D6 metabolic capacity10. 
The aim of the present study was to develop a generic PBPK 
model to predict infant exposure to maternal drugs through 
breast milk. Published clinical data on infant exposure to the 
antiretroviral drug, efavirenz, at the standard 600 mg daily dose 
was used for model validation11. Additional simulations were 
conducted to explore breast milk and plasma pharmacokinetics of 
efavirenz in mother-infant pairs at the 400 mg reduced dose 
recently approved by the WHO.
Methods
Model structure and parameterisation
The human breastfeeding model integrates a whole-body 
PBPK maternal model with a whole-body PBPK infant model 
(Figure 1). The maternal model was based on a previously vali-
dated adult model of orally administered efavirenz, an antiret-
roviral used to treat HIV infection, adapted for intramuscular 
long-acting nanoformulations12, with appropriate adjustments 
to exclude male-specific system parameters and an additional 
compartment introduced to represent the mammary gland. As 
previously described13, individual organ weights and blood 
flows were predicted from anthropometric characteristics (age, 
height, weight, body mass index, and body surface area), based 
on values reported in a HIV positive breastfeeding cohort11. The 
infant sub-model was scaled from maternal models for different 
age groups (10 days–1 month, 1–3 months, 3–6 months, and 
6–12 months) to account for age-dependent anatomical and 
physiological changes in system parameters such as organ/ 
tissue volumes and blood flows. Infants less than 10 days 
old were excluded because of residual intrauterine efavirenz 
exposure11,14. Efavirenz-specific parameters included in the model 
have been are presented in Table 1.
Modelling absorption, distribution, metabolism and 
elimination
A compartmental absorption and transit model incorporating 
both gastric emptying and small intestinal transit flow was used 
to describe drug absorption. Fraction of dose absorbed (F
a
) 
was described using effective permeability (P
eff) derived from 
Caco-2 permeability as previously described15.
Intestinal drug clearance (CLgut) was calculated from CYP3A4 
induction (IndCYP3A4), intestinal CYP3A4 abundance (AbCYP3A4), 
in vitro CYP3A4 intrinsic clearance (rCLint), and blood-to-
plasma ratio (R) using equation (1). The fraction of drug 
escaping gut metabolism (Fg) was calculated using equation 
(2), where Qgut and fu,gut are intestinal blood flow and fraction 
unbound in the intestine, respectively.
CLgut = IndCYP3A4 × AbCYP3A4 × (CYP3A4 rCLint/R)                           (1)
gut
g
gut u,gut gut
Q
F (Q f CL )= + ×
 
                                                        (2)
Page 3 of 17
AAS Open Research 2018, 1:16 Last updated: 21 MAY 2018
Figure 1.  Predicted (solid lines, mean; dotted lines, standard deviation) and observed (open circles) plasma (A) and breast milk (B) efavirenz 
concentration-time profiles in women receiving 600 mg efavirenz. Over 80% of observed data points (n = 203 paired plasma and breast milk 
samples, from 29 subjects) were within the predictive interval.
Systemic circulation was defined as a function of the rate of 
blood flow to tissues (perfusion-limited) and by a mechanism 
based approach using tissue composition-based equations as 
previously described16,17.
The abundances of CYP450 enzymes in nursing mothers were 
based on reported in vivo adult data18,19. CYP2B6 abundances 
for different infant age groups were based on data from human 
liver microsomal samples obtained from 102 infants previously 
reported by Croom et al20. A plot of CYP2B6 expression 
in individual tissue samples from birth to 1 year was 
digitised using Plot Digitizer. Samples with levels below the 
limit of detection (0.25 pmol/mg protein) were excluded20. The 
amount of microsomal protein per gram of liver (MPPGL), 
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intrinsic clearance (CLint), CYP2B6 induction (IndCYP2B6), total 
intrinsic clearance (TCLint), total apparent clearance (CLapp), 
systemic clearance (CL), and fraction escaping first-pass metab-
olism (Fh) were calculated using equation (3) to equation (9) 
as previously described12.
MPPGL =10(1.407+0.0158 × Age-0.00038 × Age2 + 0.0000024 × Age3)                                (3)
CLint = (Ind × (rCLint/R) × AbCYP × MMPGL × Wtliver))                         (4)
IndCYP2B6 = 1+(Indmax × [EFV]plasma)/(Ind50+[EFV]plasma)                     (5)
TCLint = CLint × AbCYP × Wtliver × MPPGL                                               (6)
n
app intn=1
CL TCL=∑                                                                   (7)
u apphv
app uh
Q f CL
CL Q CL f
× ×
=
+ ×                                                                (8)
Fh = 1– CL/Qhv                                                                                                                                                          (9)
Population variability
Variability in system and drug-specific parameters in both 
maternal model and the infant sub-model was introduced mainly 
through anthropometric characteristics as previously described. 
Variability in infant age was introduced using the MATLAB® 
linspace function to generate equally spaced values within 
each group. Where physiological and anatomical data were 
used, MATLAB® rule expressions, incorporating the mean, 
standard deviation, minimum and maximum parameter values, 
were used to introduce variability. Some of the parameters 
thus varied are absorption constants, microsomal protein per 
gram of liver and CYP450 enzymes abundance.
Modelling breastfeeding
Breastfeeding was described by oral dose of maternal breast 
milk twelve times a day, the concentration of efavirenz in breast 
milk ([EFV]
milk) and the corresponding infant dose of efavirenz 
per feeding session (EFV Dose
milk) were described using 
equation (10) and equation (11), respectively.
[EFV]
milk = M/PAUC0–24 × [EFV]plasma                                            (10)
Table 1. Drug-specific physicochemical properties and in vitro data for 
Efavirenz12.
Drug properties Description Values
MW Molecular weight 316
LogP Octanol-water partition coefficient 4.60
pKa Acid dissociation constant 10.2
R Oral bioavailability 0.74
PSA Polar surface area 38.33
HBD Hydrogen bond donor 1
K (mg/mL) Water solubility 0.00855
Fu Fraction unbound in plasma 0.01
Vd (L/kg) Volume of distribution at steady state 3.6
Peff (cm/s) Effective permeability (Caco-2) 2.5 × 10
-6
CLint (µL/min/pmol)
Intrinsic hepatic clearance by 
cytochrome P450 (CYP) enzymes
             rCYP1A2 CLint 0.008
             rCYP2A6 CLint 0.05
             rCYP2B6 CLint 0.55
             rCYP3A4 CLint 0.007
             rCYP3A5 CLint 0.03
IndCYP (µM) Hepatic CYPs induction
             CYP2B6 Indmax 5.76
             CYP3A4 Indmax 6.45
             CYP2B6 Ind50 0.82
             CYP3A4 Ind50 3.93
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EFV Dose
milk = Vmilk × [EFV]milk                                                (11)
= milk
therapeutic
EFV Dose
Exposure Index
EFV Dose                                                  
(12)
where [EFV]plasma is simulated efavirenz concentration in plasma, 
M/PAUC0-24 is the clinically observed milk-to-plasma AUC0-24 
ratio (median: 1.13; range: 0.50-1.93)11, V
milk is the volume of 
breast milk, and EFV Dose(therapeutic) is the recommended 
therapeutic dose of efavirenz for paediatrics, 10 mg/kg/day. In 
addition, two hypothetical milk-to-plasma ratios representing both 
ends of the observed range (0.5 and 2.0) were used to explore 
additional scenarios of infant exposure. Infant suckling rates 
from birth to 6 months of age were obtained from the literature21. 
Suckling rate at 6 months was retained for older infants up to 12 
months of age to reflect reduced breast milk intake following the 
introduction of alternative foods when exclusive breastfeeding 
ends at 6 months.
Model simulation and evaluation
The model was built and simulated using the SimBiology® 
(version 5.1, MATLAB® 2014b, MathWorks Inc., Natick, MA, 
USA). Virtual populations of nursing mothers-infant pairs (n 
= 100 per infant age group: 10 days–1 month, 1–3 months, 3–6 
months, and 6–12 months) were simulated. Simulated mothers 
received the standard 600 mg dose of efavirenz once daily and 
the infants received no medication. All model simulations were 
run using female anatomical and physiological parameters 
to simulate efavirenz pharmacokinetics during lactation and 
breastfed infants were simulated as females because of the 
expected similarities between males and females at this early 
age. Selected physiological parameters are presented in Table 2. 
Additional simulations were conducted at the recently approved 
Table 2. Key simulated anatomical and physiological parameters (mean, 
SD) for infant sub-model.
10 days-1 month 1–3 months 3–6 months 6–12 months
Age (y) 0.06 (0.02) 0.18 (0.04) 0.38 (0.07) 0.80 (0.12)
Weight (kg) 3.89 (0.58) 4.81 (0.65) 6.40 (0.80) 8.65 (1.04)
Organ Weights (kg)
Adipose 1.14 (0.57) 1.38 (0.56) 1.94 (0.61) 2.59 (0.75)
Blood 0.40 (0.00) 0.40 (0.00) 0.43 (0.01) 0.50 (0.03)
Bones 0.21 (0.04) 0.26 (0.06) 0.34 (0.07) 0.48 (0.11)
Brain1 0.40 (0.03) 0.46 (0.04) 0.58 (0.04) 0.82 (0.07)
Heart1 0.02 (0.00) 0.03 (0.01) 0.04 (0.01) 0.10 (0.03)
Intestines 0.06 (0.05) 0.08 (0.04) 0.09 (0.05) 0.12 (0.05)
Kidneys1 0.04 (0.00) 0.04 (0.00) 0.05 (0.00) 0.06 (0.00)
Liver1 0.18 (0.03) 0.22 (0.03) 0.27 (0.03) 0.34 (0.04)
Lungs1 0.06 (0.00) 0.07 (0.01) 0.08 (0.01) 0.10 (0.01)
Muscle 0.75 (0.46) 0.47 (0.38) 1.42 (0.73) 3.14 (0.95)
Pancreas1 0.01 (0.00) 0.01 (0.00) 0.01 (0.00) 0.02 (0.00)
Remaining 0.28 (0.03) 0.32 (0.04) 0.39 (0.04) 0.51 (0.06)
Skin 0.29 (0.06) 0.30 (0.05) 0.34 (0.06) 0.40 (0.05)
Spleen1 0.01 (0.00) 0.01 (0.00) 0.02 (0.00) 0.02 (0.00)
Stomach 0.10 (0.05) 0.10 (0.05) 0.11 (0.06) 0.11 (0.05)
Thymus1 0.01 (0.00) 0.02 (0.00) 0.02 (0.00) 0.02 (0.00)
Total weight 4.57 (0.10) 4.72 (0.12) 4.99 (0.14) 5.51 (0.18)
Organ Blood Flows (L/h)
Cardiac output 44.66 (5.88) 53.96 (6.47) 69.60 (7.80) 91.05 (9.70)
Adipose 1.74 (0.23) 2.10 (0.25) 2.71 (0.30) 3.55 (0.38)
Brain 14.11 (1.86) 17.05 (2.04) 21.99 (2.46) 28.77 (3.07)
Gonads 0.22 (0.03) 0.27 (0.03) 0.35 (0.04) 0.46 (0.05)
Gut 3.89 (0.51) 4.69 (0.56) 6.06 (0.68) 7.92 (0.84)
Hepatic artery 2.90 (0.38) 3.51 (0.42) 4.52 (0.51) 5.92 (0.63)
Hepatic vein 3.90 (0.38) 4.51 (0.42) 5.52 (0.51) 6.92 (0.63)
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400 mg reduced daily dose to investigate efavirenz pharma-
cokinetics in breast milk and plasma of nursing mother-infant 
pairs if the alternative recommended dose is extended to nursing 
mothers.
The validity of model estimations was confirmed by com-
parison with reference values from the literature, with 2-fold 
difference set as acceptance criteria. For organ weights and blood 
flows, data from Coppoletta et al. and Pryce et al. were used22,23. 
Pharmacokinetic parameters were evaluated at steady state and 
AUC0-24 was calculated using the trapezoidal rule. The most 
comprehensive published clinical data of efavirenz pharmacoki-
netics in human breast milk and exposure of breastfed infants11 
were used to validate predicted pharmacokinetic parameters.
Results
Breastfed infant sub-model validation
The validation of the adult model has been previously described12. 
Key anatomical and physiological parameters predicted with 
the breastfed infant sub-model, including body weight, organ 
weights and blood flows, and CYP450 enzyme expressions, 
were within 50% difference of available data for all four age 
groups. For instance, predicted cardiac output calculated as a 
function of body weight was 44 L/h in 10 days-1 month and 91 
L/h in 6-12 months infants, compared with the reference values 
of 36 L/h in new-borns and 72 L/h in 12 months old infants24. 
Predicted infant body weights, organ weights, and blood 
flows calculated as fractions of cardiac output are presented in 
Table 220,22,23. 
Model-predicted breast milk and plasma pharmacokinetics 
of efavirenz in nursing mother-infant pairs
The adult model adequately described the plasma and breast 
milk pharmacokinetics of efavirenz, with over 80% of observed 
data points (203 matched breast milk and plasma pairs from 
29 patients) falling within model predictive interval for both 
fluids (Figure 1, data plotted as mean ± SD, n = 400). The 
resulting plasma and breast milk pharmacokinetic parameters 
(AUC0-24, Cmin, and Cmax) were within 2-fold of those observed 
in a cohort of postpartum women receiving 600 mg efa-
virenz as part of their antiretroviral regimen11 (Figure 2). For 
instance, model-predicted versus observed median (range) 
breast milk AUC0–24, Cmax and Cmin were 75.0 (18.5–324) 
versus 68.5 (26.3–257) µg.hr/mL, 4.56 (1.17–16.0) versus 5.39 
(1.43–18.4) µg/mL, and 2.11 (0.38–12.3) versus 1.68 (0.316–9.57) 
µg/mL, respectively (Table 3).
Model predictions for parameters relating to breastfed infants’ 
exposure to maternal efavirenz at the 600 mg dose also gener-
ally compared well with clinical data, except for the lower end 
of drug dose from breast milk which tended to be underestimated 
(39 and 47% of observed for average and maximum dose from milk, 
respectively). However, the resulting time-averaged plasma con-
centrations of efavirenz were within 2-fold difference of observed 
data11, with average infant plasma concentration highest in 
the 10 days-1 month old at 0.27 (0.11–0.87) µg/mL, fol-
lowed by 0.19 (0.055–0.89) µg/mL in 1–3 months old, 0.18 
(0.041–0.67) µg/mL in 3–6 months old, and 0.15 (0.035–0.57) 
in 6–12 months old infants (Table 4). This trend is compara-
ble to the observed decrease from 0.19 µg/mL (0.52–0.71) in 
9 days-3 months old, to 0.15 µg/mL (0.052–0.33) in > 3–6 months 
old, and 0.10 µg/mL (0.041–0.59) in > 6 months old in our 
previously published clinical cohort11.
Additionally, two different hypothetical scenarios of milk-to-
plasma ratios representing approximately 50% and 200% of what 
has been reported were simulated to assess their implications 
for infant exposure. At the milk-to-plasma ratio of 0.5, median 
(range) maximum infant exposure index (based on the 
recommended infant therapeutic dose of 10 mg/kg) was 2.78 
(0.624–17.0) in pooled analysis of all four age groups com-
pared with 6.35 (1.02–29.2) at the milk-to-plasma ratio of 1.13. 
The exposure index increased to 11.1 (2.49–59.7) at the hypo-
thetical milk-to-plasma ratio of 2.0. The efavirenz concentra-
tion-time profiles in infant plasma for all four age groups at these 
milk-to-plasma ratios are presented in Figure 4. The combined 
10 days-1 month 1–3 months 3–6 months 6–12 months
Kidneys 4.11 (0.54) 4.96 (0.60) 6.40 (0.72) 8.38 (0.89)
Lungs 0.54 (0.07) 0.65 (0.08) 0.84 (0.09) 1.09 (0.12)
Muscle 1.74 (0.23) 2.10 (0.25) 2.71 (0.30) 3.55 (0.38)
Pancreas 0.54 (0.07) 0.65 (0.08) 0.84 (0.09) 1.09 (0.12)
Portal vein 6.42 (0.58) 7.34 (0.64) 8.89 (0.77) 11.01 (0.96)
Rest of body 2.23 (0.29) 2.70 (0.32) 3.48 (0.39) 4.55 (0.49)
Skin 1.16 (0.15) 1.40 (0.17) 1.81 (0.20) 2.37 (0.25)
Spleen 0.89 (0.12) 1.08 (0.13) 1.39 (0.16) 1.82 (0.19)
Stomach 0.40 (0.05) 0.49 (0.06) 0.63 (0.07) 0.82 (0.09)
Reference values available from Pryce et al. and/or Coppoletta et al. 1With the 
exception of pancreas in the 10 days-1 month stratum, infant organ weights and 
blood flows were within 50% fold difference of reference values.
Page 7 of 17
AAS Open Research 2018, 1:16 Last updated: 21 MAY 2018
Figure 3. Comparison of predicted versus observed breast milk pharmacokinetic parameters of efavirenz and infant exposure indices. 
All predictions were within 2-fold difference (dotted lines) of the observed values (solid line).
Figure 2. Predicted (solid lines, mean; dotted lines, standard deviation) and observed (open circles) plasma efavirenz concentration-
time profile in infants.
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Table 3. Predicted versus observed pharmacokinetic parameters of efavirenz in breast milk and plasma.
Parameters Model Predictions 
(600 mg daily dose)
Observed Data 
(600 mg daily dose)
Model Predictions 
(400 mg daily dose)
Observed Data 
(400 mg daily dose)
Breast milk AUC(0-24) (µg.hr/mL) 75.0 (18.5-324) 68.5 (26.3-257) 52.7 (13.0-290) -
Breast milk Cmax (µg/mL) 4.56 (1.17-16.0) 5.39 (1.43-18.4) 3.16 (0.810-14.6) -
Breast milk Cmin (µg/mL) 2.11 (0.38-12.3) 1.68 (0.316-9.57) 1.51 (0.285-10.7) -
Plasma AUC(0-24) (µg.hr/mL) 67.2 (26.3-360) 60.7 (26.8-177) 46.9 (18.7-243) 49.9 (14.8-285)
Plasma Cmax (µg/mL) 4.13 (2.08-17.7) 4.63 (2.05-9.76) 2.84 (1.44-12.0) 2.51 (0.95-12.2)
Plasma Cmin (µg/mL) 1.95 (0.47-13.6) 2.03 (0.755-6.74) 1.40 (0.352-9.23) 1.46 (0.169-11.3)
Data are presented as median (range). Breast milk and maternal plasma data are from 400 virtual nursing mothers. Previously published data for 
the 600 mg standard dose involved 29 mothers (Ref. 11). Published data for the 400 mg reduced dose are from a cohort of non-breast feeding 
adults in the ENCORE1 trial (Ref. 26). Abbreviations: AUC(0-24), area under the concentration-time curve during a 24-hour dosing interval; Cmax, 
maximum plasma concentration; Cmin, minimum plasma concentration.
Table 4. Indices of infant exposure to maternal efavirenz from breast milk at clinically 
observed milk-to-plasma ratio of 1.13 (0.50–1.93).
400 mg 600 mg
Number of Feeds Per Day 12 12
Exposure Indices at 10 Days-1 Month
Maximum efavirenz dose from milk (µg/kg/day) 593 (219 - 1980) 870 (317 - 2920)
Infant plasma efavirenz conc. (µg/mL) 0.21 (0.079 - 0.73) 0.27 (0.10 - 1.0)
Exposure Index (EI, %)* 5.9 (2.2-20) 8.7 (3.2-29)
Infants with EI Above 10.0 (%) 13 36
Exposure Indices at 1-3 Months
Maximum efavirenz dose from milk (µg/kg/day) 481 (167 - 1650) 702 (241 - 2430)
Infant plasma efavirenz conc. (µg/mL) 0.14 (0.042 - 0.65) 0.19 (0.055 - 0.87)
Exposure Index (EI, %) 4.8 (1.7-16) 7.0 (2.4-24)
Infants with EI Above 10.0 (%) 10 25
Exposure Indices at 3-6 Months
Maximum efavirenz dose from milk (µg/kg/day) 383 (95 - 1310) 558 (138 - 1940)
Infant plasma efavirenz conc. (µg/mL) 0.13 (0.031 - 0.78) 0.18 (0.041 - 0.67)
Exposure Index (EI, %) 3.8 (0.95-13) 5.6 (1.4-19)
Infants with EI Above 10.0 (%) 3 12
Exposure Indices at 6-12 Months
Maximum efavirenz dose from milk (µg/kg/day) 287 (70.8 - 961) 418 (102 - 1420)
Infant plasma efavirenz conc. (µg/mL) 0.11 (0.026 - 0.65) 0.15 (0.035 - 0.57)
Exposure Index (EI, %) 2.9 (0.71-9.6) 4.2 (1.0-14)
Infants with EI Above 10.0 (%) 0 5
Data are presented as median (range). Predicted infant plasma efavirenz concentrations (n = 100 per 
age group) did not change significantly during the dosing interval and average predicted values are 
presented.
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Figure 4. Infant efavirenz concentration-time profiles at the observed and hypothetical milk-to-plasma ratios of 1.13, 0.5, and 0.2. 
Simulated concentration-time profiles were relatively flat in all age groups, reflecting the frequent doses received from breast milk. At the 
observed milk-to-plasma ratio of 1.13, the median (range) infant plasma concentration was highest in the 10 days–1 month old at 0.27 
(0.11–0.87) µg/mL and lowest in 6–12 months old at 0.15 (0.035–0.57) µg/mL.
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median (range) plasma efavirenz concentration averaged 
over the dosing interval for each infant were 0.104 (0.018–0.75) 
µg/mL at milk-to-plasma ratio of 0.5 and 0.30 (0.057–1.26) 
µg/mL at milk-to-plasma ratio of 2.0, compared with 0.19 
(0.035–1.00) µg/mL at milk-to-plasma ratio of 1.13 and the 
previously reported 0.16 ng/mL (0.029–1.36)11.
Breast milk pharmacokinetics and breastfed infants’ 
exposure in the context of 400 mg reduced dose of 
efavirenz
Further simulations were conducted for the four infant age 
groups at the observed milk-to-plasma ratio of 1.13 to explore the 
potential impact of reducing efavirenz dose to 400 mg on breast 
milk pharmacokinetics and plasma exposure in nursing mother-
infant pairs. Breast milk C12 and Cmin were below 1.0 µg/mL 
in 11.5 and 28% of simulated subjects, respectively, compared 
with 2.5 and 14.5% at the standard 600 mg dose. Plasma C12 
and C
min were below 1.0 µg/mL in 5 and 32% of simulated 
subjects, respectively, compared with 0 and 15% at the stand-
ard 600 mg dose. However, the number of subjects with 
C
max
 above the 4.0 µg/mL toxicity threshold reduced from 
50% at 600 mg to 24% at the reduced 400 mg daily dose. In 
pooled analysis, the resulting plasma concentration was 0.15 
(0.026–0.78) µg/mL, approximately 25% lower than simulated 
exposure at 600 mg. The maximum exposure index was 4.29 
(0.708–19.8), about 30% lower than at 600 mg and above 10% 
in 6.5% of simulated infants, compared with 18% of simulated 
infants at 600 mg. The indices of foetal exposure for the different 
age groups are presented on Table 4.
Discussion
PBPK modelling was applied for the prediction of breast 
milk and plasma pharmacokinetics of the antiretroviral drug 
efavirenz in nursing mother-infant pairs. The model integrates a 
previously validated whole-body oral adult PBPK model12 with 
a whole-body breastfed infant PBPK sub-model. System and 
drug-specific parameters for the infant sub-model were either 
obtained from the literature or scaled from the adult model, 
and variability was introduced to reflect in vivo observations. 
Breastfeeding was successfully described by repeated (2 hourly) 
ingestion of a volume of breast milk controlled by infant 
suckling rate25 Simulated breast milk and plasma pharma-
cokinetic parameters, as well as various measures of breastfed 
infants’ exposure, showed good agreement with observed data 
for the standard 600 mg daily dose of efavirenz11, except for the 
lower end of infant plasma concentration range which tended to 
be underestimated. Plasma pharmacokinetic parameters in vir-
tual subjects who received the reduced 400 mg dose were simi-
lar to those observed in adults who received the 400 mg in 
the ENCORE1 trial26. About 5% of simulated subjects were 
predicted to have C12 below the recommended 1.0 µg/mL with the 
400 mg dose, similar to the 4.7% observed in the trial.
PBPK models have been used to describe plasma and 
intracellular efavirenz pharmacokinetics following oral and 
intramuscular administrations, respectively12,27. In addition to 
accurately predicting plasma pharmacokinetics as in previous 
models, breast milk pharmacokinetics predicted by the current 
model are very similar to observed clinical data11. Willmann 
et al used similarly coupled PBPK models for mother-infant 
pairs to assess the risk of opioid poisoning to breast-fed 
neonates10. Other previous applications in human lactation stud-
ies have been limited to environmental risk assessments where 
they are used to quantitatively describe the lactational transfer 
of inhaled contaminants5, trichloroethylene and its metabolite6, 
tetrachloroethylene and associated cancer risk for breast-
fed infants7,8, perchlorate and iodide including inhibition of 
iodide thyroidal uptake by perchlorate9. An extensive review by 
Corley et al. describes the underlying assumptions, model 
structures, data and methods used in the development and 
validation of these early PBPK models28. Similar models have 
been described for polychlorinated biphenyls29, co-exposure 
to polychlorinated biphenyls and methyl mercury30, persistent 
organic pollutants (including an initial infant body burden to 
represent intrauterine exposure)31, manganese25, and perfluoro-
alkyl carboxylates and sulfonates32,33. The use of a population 
pharmacokinetic modelling approach to predict infant exposure 
through breast milk has been reported for a number of drugs and 
was recently reviewed by Anderson et al.34 Examples include 
tramadol and its O-desmethyl metabolite35, fluoxetine and its 
active metabolite norfluoxetine36, nevirapine37, and parecoxib 
and its active metabolite valdecoxib38. However, a major advan-
tage of the PBPK approach described here is that it does not 
require clinical pharmacokinetics data for model building 
unlike the population pharmacokinetics approach. Additionally, 
PBPK modelling offers higher fidelity to actual physiological 
conditions and can be used to simulate best- and worse-case 
scenarios once the requisite in vitro drug data have been 
integrated into with available physiological and anatomical data.
Replicating the ontogeny of drug metabolism enzymes is 
one of the major challenges in the development of paediatric 
PBPK model. Children often display developmentally unique 
differences in drug disposition compared to adults, making 
simple scaling using anthropometric characteristics unreliable. 
For instance, paediatric doses of efavirenz derived from adult 
dose using simple allometric scaling have been reported to 
result in sub-therapeutic and higher variability in plasma 
concentrations compared to adults39. The CYP2B6 hepatic 
cytochrome P450 isoform accounts for over 90% of efavirenz 
metabolism. Polymorphisms in CYP2B6 gene is known to cause 
significant inter-individual variability in CYP2B6 enzyme 
expression and activity, resulting in variability in the metabo-
lism of substrate drugs. We previously demonstrated that infant 
plasma efavirenz concentration resulting from breast milk expo-
sure was influenced by both maternal and infant CYP2B6 geno-
types11. Therefore, we used paediatric CYP2B6 protein expres-
sion data available in the literature20, and replicated in vivo 
variability using MATLAB rule expression that incorporated 
the mean, standard deviation, minimum and maximum values 
for each age stratum. Further variability in the resulting CYP2B6 
intrinsic clearance was introduced through simple linear 
interpolation of age which modulates milligram of micro-
somal protein per gram of liver. In view of their minimal role 
in efavirenz metabolism, CYP2A6, CYP3A4, and CYP3A5 
intrinsic clearances were scaled from adult values through 
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infant age, and variability in each age stratum was introduced by 
linear interpolation.
This approach adequately described infant plasma efavirenz 
concentrations resulting from breastfeeding in the presence 
of maternal efavirenz for the different age groups, demon-
strating the reasonableness of age-related changes in model 
parameters as well as the associated scaling and variability. As 
with the clinical data, model predictions indicate that exposure 
to maternal efavirenz from breast milk resulted in measurable 
plasma concentrations in infants. The implications for possible 
development of drug resistance in infants who become infected 
call for further clinical investigation. The model can be used 
for other drug classes and therapeutic areas, provided the 
requisite drug-specific parameters are available or accurately 
predictable from other known parameters. The hypothetical 
milk-to-plasma ratios were included to illustrate the possibility 
of using this model to simulate best- and worse-case scenarios 
even where the milk-to-plasma ratio is unknown.
However, a number of limitations are identifiable in this model. 
First, the lack of milk-to-plasma ratio prediction component 
means that only hypothetical best- and worse-case scenarios 
can be predicted for drugs with no observed milk-to-plasma 
ratio. A number of models have appeared in the literature for 
predicting the milk-to-plasma ratio40–43. Unfortunately, their 
utility has been limited by lack of universal accuracy which may 
constitute additional source of uncertainty in this type of model. 
In addition, the present model did not consider the potential 
role of drug transporters in breast milk excretion because efa-
virenz is not a known substrate of any transporter in humans44,45. 
However, this can be incorporated for drugs with known 
active transport mechanisms in mammary gland as previ-
ously described for OATP1B1/1B3-mediated irbesartan hepatic 
uptake46. For instance, ABCG2 is known to be highly expressed 
in lactating human mammary gland47, involved in the secretion 
of its substrates into breast milk48,49, and can be affected by 
polymorphisms in ABCG2 gene50. Integrating such approaches 
with the current model can potentially extend its application 
to drugs with no available breast milk data and can be used as a 
tool in the drug development process. Lastly, the outputs of any 
model are only as reliable as the quality of input data.
In conclusion, the breastfeeding PBPK model described here 
opens up opportunities for expanding our understanding of 
infant exposure to maternal drugs through breast milk, including 
during the drug development process. Its application 
can help in bridging existing gaps and pave the way for evidence-
based recommendations for drug use during lactation.
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The equation and model parameter values representing the mammary gland and milk compartment need
to be shown in the paper. Include assumptions. Since this is new to your paper please include what you
did.  Is only the free concentration of the drug assumed to transfer to milk from plasma (I assume so)?  Is
there bi-directional transfer of the drug into and out of the milk compartment and plasma?  Blood flow to
mammary gland changes during lactation. The volume of maternal fat increases during pregnancy and
decreases during lactation. This drug is lipophilic, thus fat is an important model parameter. Perhaps a
sensitivity analysis would reveal this.
It is not clear if the maternal physiology initial conditions were those of a pregnant woman at birth?  This
would be the normal approach and then describe the changes in maternal physiology during lactation. 
Scaling of physiology for a neonate/infant less than 1-2 years of age is not recommended because of
nonlinear growth not described by simple allometric functions.  The authors are referred to Claassen et al.
2015. Current Pharmaceutical Design, 21, 5688-5698 for PBPK modeling of early life considerations for
drugs.   
To use a data set which contains mother-infant paired blood samples and breast milk samples is a
wonderful situation to be in.  It was unclear when samples of breast milk were taken relative to
mother-infant blood samples and if mother-infant blood samples taken within a short period of time of
each other?  If so, plotting individual model predictions of mother’s blood and breast milk concentrations
vs infant blood concentration would be worthwhile to understand how your model performs and gain
insights into the nature of the mother-infant variability.
The breast milk and maternal plasma drug levels (bound plus free) track each other, except for some high
levels in breast milk.  This suggests fat:plasma partitioning of this drug is high and the drug quickly enters
into milk (as shown in Fig. 1).  The % fat in breast milk can be found in the literature, thus you can estimate
a milk:plasma partition coefficient and predict milk levels of drug based on model predicted free
concentration in plasma.
How do you predict the bound and free drug in infant plasma? 
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How do you predict the bound and free drug in infant plasma? 
Is metabolism in the mother and infant based on model predicted free concentration of drug?
Is it expected that at birth the baby has a body burden of drug?  If so, using cord blood values you
could simulate the neonate to estimate the total drug burden, not just hair.  Then your starting conditions
would include this ‘background’ level of drug when lactational transfer starts.  Including hair has
successfully been included in PBPK models for metals (adults) if you are interested.
You need to consider actual birth weights for this study if you did not, not published birth weights.  A new
infant growth paper contains growth equations for body weight and height: [Troutman JA, Sullivan MC,
Carr GJ, Fisher J. Birth Defects Res.   Mar 14. doi: 10.1002/bdr2.1214. [Epub ahead of print].2018
Unfortunately we do not have many measured blood flows in neonate/infant/child. Read Claassen et al. 
2015 or other pediatric PBPK modeling papers for drugs. Your paper infers that blood flow rates to all the
organs are known, which is not really true.
One other modeling lactation paper where mother-infant pair data exist with breast milk is found in Fisher
2015 for the nutrient iodine (PLOS ONE | DOI:10.1371/journal.pone.0149300 March 1, 2016).et al. 
Perhaps this may be of some value to you.
Are the high levels of drug in maternal plasma and breast milk correspond to the high levels in the nursing
infant plasma 20+ hours after maternal dose of the drug?  This is one reason to examine individual
datasets for mother-infant plasma and breast milk.
Since you used Matlab consider publishing the code as a supplemental.  This way what you did will be
fully understood by modelers who write script.
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